The table below shows Viridian Therapeutics, Inc.DE's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$276.39M
-$232.32M
-$184.17M
-$93.84M
-$54.58M
-$29.78M
Capital expenditure
$495.00K
$511.00K
$898.00K
$797.00K
$338.00K
$42.00K
Investing cash flow
-$37.56M
-$228.65M
-$94.25M
-$115.13M
-$74.29M
-$50.48M
Dividends paid
-
-
-
-
VRDN operating cash flow (10-K history)
Viridian Therapeutics, Inc.DE reported operating cash flow of -$276.39M for fiscal year 2025. That is down 19.0% from -$232.32M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$14.76M (FY 2016) to -$276.39M. Figures come from the company's audited annual reports as filed with the SEC.